Telehealth & Digital Health

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

New data on Eli Lilly's oral GLP-1, orforglipron, shows superior results over rivals, promising a new era for millions of needle-averse patients.

Otto Aerospace's Phantom 3500 just passed a major FAA milestone, but this is more than paperwork. It's a blueprint for certifying radical aviation tech.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As dementia costs Ontario $30 billion annually, a new task force is not just another committee. It's a strategic blueprint for dismantling a broken system.

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

A new generation of men is shattering the stigma around mental health at work, but a startling retention gap reveals a deeper crisis for employers.

A Stanford spinout just revealed a wearable that measures the body's master stress hormone in real time. This isn't just a new gadget; it's a fundamental shift.

A new medical AI, trained on vast proprietary data, is now live in a US clinic. It reasons like a physician, not a scribe, setting a new bar for trust and accuracy.

New research shows 'Food is Medicine' programs thrive when paired with human coaching, offering a potent, scalable model for tackling chronic disease.

Dr. Brian Covino's top honor signals a shift in health tech, where AI doesn't replace doctors but learns from them. Can this model fix our broken system?

Septerna's novel oral drug for hypoparathyroidism could end the tyranny of injections and supplements, but its success hinges on a bigger bet: a new system for drugging life's most difficult molecular targets.

Luxardo's new Decaf Espresso Liqueur isn't just a new bottle. It's a strategic move to capture the mindful drinking trend and dominate the espresso martini scene.

As return-to-office mandates clash with the needs of 5 million Canadians with migraine, the economic toll of inaction is mounting for employers.

As rural hospitals face financial collapse, a new wave of AI-powered technology is proving it can stabilize finances and preserve access to essential care.

With healthcare drowning in a $1 trillion administrative burden, CAQH's rebrand to DataSpring is more than a name change—it's a high-stakes bet.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

New trial data shows Sequel Med Tech's twiist™ AID system could bring much-needed simplicity and safety to millions with insulin-treated type 2 diabetes.

A landmark study validates Ceribell's AI in predicting neurological outcomes, signaling a major shift in critical care and bolstering its competitive edge.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.